vs
ICU MEDICAL INC（ICUI）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
SCANSOURCE, INC.的季度营收约是ICU MEDICAL INC的1.4倍（$766.5M vs $540.7M），SCANSOURCE, INC.净利率更高（2.2% vs -2.9%，领先5.1%），SCANSOURCE, INC.同比增速更快（2.5% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $28.9M），过去两年SCANSOURCE, INC.的营收复合增速更高（0.9% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
ICUI vs SCSC — 直观对比
营收规模更大
SCSC
是对方的1.4倍
$540.7M
营收增速更快
SCSC
高出16.7%
-14.1%
净利率更高
SCSC
高出5.1%
-2.9%
自由现金流更多
ICUI
多$7.1M
$28.9M
两年增速更快
SCSC
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $766.5M |
| 净利润 | $-15.7M | $16.5M |
| 毛利率 | 37.5% | 13.4% |
| 营业利润率 | 1.0% | 2.3% |
| 净利率 | -2.9% | 2.2% |
| 营收同比 | -14.1% | 2.5% |
| 净利润同比 | 34.0% | -3.3% |
| 每股收益（稀释后） | $-0.63 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUISCSC
| Q4 25 | $540.7M | $766.5M | ||
| Q3 25 | $537.0M | $739.6M | ||
| Q2 25 | $548.9M | $812.9M | ||
| Q1 25 | $604.7M | $704.8M | ||
| Q4 24 | $629.8M | $747.5M | ||
| Q3 24 | $589.1M | $775.6M | ||
| Q2 24 | $596.5M | $746.1M | ||
| Q1 24 | $566.7M | $752.6M |
净利润ICUISCSC
| Q4 25 | $-15.7M | $16.5M | ||
| Q3 25 | $-3.4M | $19.9M | ||
| Q2 25 | $35.3M | $20.1M | ||
| Q1 25 | $-15.5M | $17.4M | ||
| Q4 24 | $-23.8M | $17.1M | ||
| Q3 24 | $-33.0M | $17.0M | ||
| Q2 24 | $-21.4M | $16.1M | ||
| Q1 24 | $-39.5M | $12.8M |
毛利率ICUISCSC
| Q4 25 | 37.5% | 13.4% | ||
| Q3 25 | 37.4% | 14.5% | ||
| Q2 25 | 37.9% | 12.9% | ||
| Q1 25 | 34.7% | 14.2% | ||
| Q4 24 | 36.1% | 13.6% | ||
| Q3 24 | 34.8% | 13.1% | ||
| Q2 24 | 34.8% | 13.0% | ||
| Q1 24 | 32.7% | 12.6% |
营业利润率ICUISCSC
| Q4 25 | 1.0% | 2.3% | ||
| Q3 25 | 2.6% | 3.5% | ||
| Q2 25 | 1.9% | 3.3% | ||
| Q1 25 | 2.1% | 3.2% | ||
| Q4 24 | 6.0% | 2.5% | ||
| Q3 24 | 1.4% | 2.3% | ||
| Q2 24 | 1.3% | 2.9% | ||
| Q1 24 | -1.9% | 2.3% |
净利率ICUISCSC
| Q4 25 | -2.9% | 2.2% | ||
| Q3 25 | -0.6% | 2.7% | ||
| Q2 25 | 6.4% | 2.5% | ||
| Q1 25 | -2.6% | 2.5% | ||
| Q4 24 | -3.8% | 2.3% | ||
| Q3 24 | -5.6% | 2.2% | ||
| Q2 24 | -3.6% | 2.2% | ||
| Q1 24 | -7.0% | 1.7% |
每股收益（稀释后）ICUISCSC
| Q4 25 | $-0.63 | $0.75 | ||
| Q3 25 | $-0.14 | $0.89 | ||
| Q2 25 | $1.43 | $0.87 | ||
| Q1 25 | $-0.63 | $0.74 | ||
| Q4 24 | $-0.97 | $0.70 | ||
| Q3 24 | $-1.35 | $0.69 | ||
| Q2 24 | $-0.88 | $0.66 | ||
| Q1 24 | $-1.63 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $83.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $910.9M |
| 总资产 | $4.1B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUISCSC
| Q4 25 | — | $83.5M | ||
| Q3 25 | — | $124.9M | ||
| Q2 25 | — | $126.2M | ||
| Q1 25 | — | $146.3M | ||
| Q4 24 | $308.6M | $110.5M | ||
| Q3 24 | $312.5M | $145.0M | ||
| Q2 24 | $302.6M | $185.5M | ||
| Q1 24 | $251.4M | $159.1M |
股东权益ICUISCSC
| Q4 25 | $2.1B | $910.9M | ||
| Q3 25 | $2.1B | $914.0M | ||
| Q2 25 | $2.1B | $906.4M | ||
| Q1 25 | $2.0B | $901.7M | ||
| Q4 24 | $2.0B | $900.7M | ||
| Q3 24 | $2.0B | $920.9M | ||
| Q2 24 | $2.0B | $924.3M | ||
| Q1 24 | $2.1B | $944.1M |
总资产ICUISCSC
| Q4 25 | $4.1B | $1.7B | ||
| Q3 25 | $4.1B | $1.7B | ||
| Q2 25 | $4.1B | $1.8B | ||
| Q1 25 | $4.2B | $1.7B | ||
| Q4 24 | $4.2B | $1.7B | ||
| Q3 24 | $4.3B | $1.8B | ||
| Q2 24 | $4.3B | $1.8B | ||
| Q1 24 | $4.3B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $30.8M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $28.9M |
| 自由现金流率自由现金流/营收 | 6.6% | 3.8% |
| 资本支出强度资本支出/营收 | 4.6% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.87× |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUISCSC
| Q4 25 | $60.6M | $30.8M | ||
| Q3 25 | $56.7M | $23.2M | ||
| Q2 25 | $11.2M | — | ||
| Q1 25 | $51.3M | $66.1M | ||
| Q4 24 | $40.2M | $-6.2M | ||
| Q3 24 | $36.1M | $44.8M | ||
| Q2 24 | $82.0M | — | ||
| Q1 24 | $45.8M | $160.2M |
自由现金流ICUISCSC
| Q4 25 | $36.0M | $28.9M | ||
| Q3 25 | $27.6M | $20.8M | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $36.7M | $64.6M | ||
| Q4 24 | $16.1M | $-8.2M | ||
| Q3 24 | $16.2M | $42.5M | ||
| Q2 24 | $62.5M | — | ||
| Q1 24 | $29.9M | $157.7M |
自由现金流率ICUISCSC
| Q4 25 | 6.6% | 3.8% | ||
| Q3 25 | 5.1% | 2.8% | ||
| Q2 25 | -1.5% | — | ||
| Q1 25 | 6.1% | 9.2% | ||
| Q4 24 | 2.6% | -1.1% | ||
| Q3 24 | 2.7% | 5.5% | ||
| Q2 24 | 10.5% | — | ||
| Q1 24 | 5.3% | 21.0% |
资本支出强度ICUISCSC
| Q4 25 | 4.6% | 0.3% | ||
| Q3 25 | 5.4% | 0.3% | ||
| Q2 25 | 3.6% | 0.3% | ||
| Q1 25 | 2.4% | 0.2% | ||
| Q4 24 | 3.8% | 0.3% | ||
| Q3 24 | 3.4% | 0.3% | ||
| Q2 24 | 3.3% | 0.2% | ||
| Q1 24 | 2.8% | 0.3% |
现金转化率ICUISCSC
| Q4 25 | — | 1.87× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 12.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
